263 results about "Galacturonic acid" patented technology

The invention provides modified acidic polysaccharide of lithocarpus litseifolius. The modified acidic polysaccharide is prepared from natural acidic polysaccharide of lithocarpus litseifolius through a chemical method or an enzyme method. Every 100 mg of the modified acidic polysaccharide of lithocarpus litseifolius contains 89.75 mg + / -1.04 mg to 90.67 mg + / -1.46 mg of total polysaccharide. The total uronic acid content is 23.70 mg + / -1.58 mg to 71.74 mg + / -2.07 mg; total bound phenol: 2.06 mg of GAE + / -0.06 mg of GAE-4.56 mg of GAE + / -0.04 mg of GAE (equivalent weight of gallic acid); the esterification degree is 3.72% + / -0.90% to 34.98% + / -0.62%; the molecular weight is (0.562 + / -0.012) * 10 < 4 > Da-(4.268 + / -0.055) * 10 < 4 > Da; the proportion of the galacturonic acid glycan (HG) is 15.28% to 65.02%; the ratio of the type I rhamnogalacturonan (RG-I) is 28.47% to 72.37%; and the length of a side chain is 0.44 to 10.31. The invention further provides a preparation method and application of the lithocarpus litseifolius modified acidic polysaccharide. The lithocarpus litseifolius modified acidic polysaccharide prepared by the invention has remarkable immunoregulatory activity, and especially has better immunocompetence when being used for removing arabinose side chains and reducing galactose side chains.

The invention belongs to the field of new application of medicines, and particularly relates to gastrodia elata polysaccharide and application thereof. The gastrodia elata polysaccharide component GEP-2 is separated from crude gastrodia elata polysaccharide, structural characterization detection is conducted on the GEP-2, the result shows that the gastrodia elata polysaccharide GEP-2 is prepared from, by mass, 89.08% of glucose, 2.40% of galactose, 7.12% of galacturonic acid, 0.86% of arabinose and 0.54% of rhamnose, and the animal experiment result shows that the GEP-2 relieves the symptoms of mouse colitis, relieves weight loss and shortens the colon length; the traditional Chinese medicine composition has the advantages of reducing serum TNF-alpha, IL-1beta and IL-6 proinflammatory cytokine levels, improving the intestinal barrier function, reducing inflammatory cell infiltration, regulating the intestinal flora composition structure of mice and relieving ulcerative colitis.

The invention provides homogenized pitaya polysaccharide as well as a preparation method and application thereof, and belongs to the technical field of polysaccharide extraction and purification. The homogenized pitaya polysaccharide is a polysaccharide of which the monosaccharide is composed of mannose, glucosamine hydrochloride, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose, the relative molecular weight is 8.08 * 10 < 4 > Da, and the corresponding molar ratio is (0.181): (0.250): (16.544): (12.762): (3.793): (0.739): (51.014): (14.716). The invention further provides a preparation method of the homogenized pitaya polysaccharide and application of the homogenized pitaya polysaccharide in preparation of lipid-lowering and sugar-lowering drugs. The homogenized pitaya polysaccharide disclosed by the invention has an obvious lipid-lowering and blood-glucose-reducing effect, is from a natural product, so that the homogenized pitaya polysaccharide has no toxic or side effect and can be used for preparing lipid-lowering and blood-glucose-reducing medicines.

The invention relates to the field of establishment of fingerprints of traditional Chinese medicinal materials, in particular to an establishment method and application of a salvia miltiorrhiza polysaccharide HPLC (High Performance Liquid Chromatography) fingerprint. The establishment method comprises the following steps: preparation of a test solution: taking a salvia miltiorrhiza polysaccharide hydrolysis solution, carrying out derivatization in a reaction bottle, and passing through a 0.1-0.3 [mu] m microporous filter membrane; preparing a reference substance solution, namely weighing mannose, ribose, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose reference substances, and preparing into a mixed reference substance solution; performing HPLC (high performance liquid chromatography) determination; and establishing the salvia miltiorrhiza polysaccharide HPLC fingerprint spectrum. According to the method, the difference of monosaccharide composition and content in salvia miltiorrhiza medicinal materials from different producing areas and the spectrum-effect relationship between antioxidant activity and anticoagulant activity are clarified, and a certain reference basis is provided for quality control and evaluation of the salvia miltiorrhiza medicinal materials from the aspect of polysaccharide.

The invention relates to gardenia polysaccharide as well as a preparation method and application thereof. The gardenia polysaccharide comprises the following monosaccharide units: rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose, or mainly comprises rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose; the molar ratio of rhamnose to glucuronic acid to galacturonic acid to glucose to galactose to arabinose in the gardenia polysaccharide is (3-15): (1-8): (4-18): (1-6): (15-35): (25-70). According to the gardenia polysaccharide, FFA induced mouse primary parenchymal hepatic cell lipid accumulation can be reduced, no obvious cytotoxic effect exists, CDAHFD diet induced hepatic fibrosis can be reduced, and the gardenia polysaccharide has a good effect of preventing and / or treating non-alcoholic steatohepatitis.

The application provides a Huangdache oligosaccharide with GLP-1 agonist activity and application thereof, and belongs to the technical field of medicines. 3 The oligosaccharide component ELYP-3 has a molecular weight of 3.2*10 3 Da, and the molar ratio of monosaccharides is rhamnose:galacturonic acid:glucose:galactose:arabinose = 1:32.42:45.37:9.11:6.54. The Huangdache oligosaccharide fragment obtained by glycosidase degradation has significant hypoglycemic and weight loss activities, the preparation process is simple, specific and green, and provides scientific basis and theoretical support for the development of natural GLP-1 agonists. Meanwhile, the functional oligosaccharide provides a wide application prospect for the development of medicines with blood glucose regulation.

The invention relates to rhodiola rosea pectic polysaccharide and application thereof.The sugar chain structure of the rhodiola rosea pectic polysaccharide is shown in the formula I. In the formula I, Glc is a glucose residue, GalA is a galacturonic acid residue, Ara is an arabinofuranose residue, and MeO is a methoxyl group; wherein m is an integer selected from 10 to 40; n is an integer selected from 1 to 50. The rhodiola rosea pectic polysaccharide can significantly improve mouse liver fatty degeneration induced by high fructose and relieve liver injury, and has a good application prospect in improvement of non-alcoholic fatty liver.

The invention relates to the field of medicines, foods or health-care products, in particular to big-fruit hawthorn heteropolysaccharide as well as a preparation method and application thereof. The large-fruit hawthorn heteropolysaccharide is prepared from galacturonic acid, glucuronic acid, mannose, xylose, arabinose, glucose, galactose, fucose and rhamnose. The weight-average molecular weight of the big fruit hawthorn heteropolysaccharide is 81.6 kDa to 157.3 kDa. The product has unique structures of complex monosaccharide composition, low molecular weight, appropriate uronic acid content, low esterification degree and the like; compared with CP which is single in structure and high in esterification, the CP is better in oxidation resistance and bile acid binding capacity; compared with hawthorn polysaccharide with low uronic acid content and high molecular weight, the hawthorn polysaccharide has the advantages that the enzyme inhibition activity is obviously enhanced, and the hawthorn polysaccharide has a wide prospect in development of functional food, health care products or medicines for regulating blood sugar / blood fat, resisting oxidation and preventing metabolic syndromes.

The present invention provides compositions and methods for improving bone formation, bone mass, and / or strength, and / or treating or preventing bone loss, such as senescent bone loss, in a subject in need of such therapy. The composition comprises a homogeneous polysaccharide, or a pharmaceutically acceptable ester or salt thereof, or a pharmaceutically acceptable solvate thereof, or any combination thereof, and a pharmaceutically acceptable excipient. The homogeneous polysaccharide is mainly composed of arabinose, galactose, rhamnose and galacturonic acid as monomeric units. Such methods comprise administering to a subject in need thereof an effective dose of such a composition.

The invention discloses application of uncaria acidic polysaccharide URP-2 in preparation of an anti-esophageal cancer drug, and belongs to the technical field of antitumor of medicinal plant polysaccharide. According to the method, a method for extracting the uncaria total polysaccharide by boiling water and precipitating the uncaria total polysaccharide by ethanol is adopted, and a DEAE DE-52 cellulose column and sephadex column purification technology is combined, so that the separation of the uncaria acidic polysaccharide component is realized, and the uncaria acidic polysaccharide URP-2 is obtained. The uncaria acidic polysaccharide URP-2 comprises the following components in mole percent: 14.11% of arabinose, 12.64% of rhamnose, 6.48% of galactose, 5.00% of glucose and 61.77% of galacturonic acid. Experiments show that the uncaria acidic polysaccharide URP-2 has remarkable anti-esophageal cancer activity, so that a potential experimental basis and a new strategy are provided for applying the uncaria acidic polysaccharide URP-2 to clinical treatment of esophageal cancer.

The invention firstly discloses application of portulaca oleracea polysaccharide in preparation of the medicine for treating psoriasis, the medicine for treating psoriasis can improve psoriasis-like skin injury and reduce skin tissue inflammation, and the portulaca oleracea polysaccharide is single-component pure polysaccharide extracted from portulaca oleracea and purified. The monosaccharide composition is composed of all or several monosaccharides of rhamnose, arabinose, galactose, glucose, xylose and galacturonic acid, and the molecular weight of the monosaccharide composition is 80-200 kDa. The invention further discloses application of the purslane polysaccharide in preparation of drugs for treating psoriasis and application of the purslane polysaccharide in preparation of cosmetics and medical auxiliary materials for relieving psoriasis-like skin injury. The purslane polysaccharide disclosed by the invention is high in purity, clear in structure and high in safety, has a good psoriasis treatment effect, is superior to dexamethasone in curative effect, can be used as a skin external medicine, a cosmetic, a medical instrument and a medical auxiliary material, and has various potential application values.

The invention relates to the technical field of plant polysaccharides, and particularly discloses a red-knees herb polysaccharide and a preparation method and application thereof, the peak top molecular weight of the red-knees herb polysaccharide is 33.9 KDa, the weight-average molecular weight of the red-knees herb polysaccharide is 42.8 KDa, the number-average molecular weight of the red-knees herb polysaccharide is 10.0 KDa, and the red-knees herb polysaccharide is mainly composed of galacturonic acid, galactose, arabinose, rhamnose and glucuronic acid. According to the preparation method of the red-knees herb polysaccharide, by optimizing process parameters and controlling the reasonable solid-liquid ratio, heating temperature and heating time, the dissolution rate of the polysaccharide is increased, the dissolution rate of impurities is reduced, and the yield of the red-knees herb polysaccharide is increased. The red-knees herb polysaccharide is used as a raw material, ethanol is used for alcohol precipitation, polysaccharide components are precipitated, impurities are preliminarily removed, then macroporous resin is used for purification, the recovery rate of polysaccharide and the removal rate of impurities such as pigment and protein are improved by screening optimization and pretreatment of the macroporous resin, and the total sugar content of the purified red-knees herb polysaccharide is 80% or above. Use of toxic chemical reagents is avoided, and the preparation method is safe and efficient.

The invention discloses stropharia rugoso-annulata polysaccharide as well as a preparation method and application thereof. The monosaccharide of the stropharia rugoso-annulata polysaccharide disclosed by the invention comprises glucose, galactose, mannose and galacturonic acid; the weight-average molecular weight of the stropharia rugoso-annulata polysaccharide is 1.4712 * 10 < 4 > to 1.623 * 10 < 4 > Da; the main chain of the stropharia rugoso-annulata polysaccharide contains-> 6)-alpha-D-(O-Me)-Galp-(1->, 1, 6-Glc, 1, 3-Man and 1.3-Gal exist in the main chain or a side chain, and terminal residues contain T-Glc and T-Gal. According to the invention, by constructing a DSS induced UC mouse model, the influence of Stropharia rugosoannulata polysaccharide (SRP1) on UC mice is investigated. Results show that the stropharia rugoso-annulata polysaccharide has a certain treatment effect on ulcerative colitis. In-vivo experiments show that the stropharia rugoso-annulata polysaccharide disclosed by the invention can increase abundance of bacteroides and thick-wall funguses and reduce abundance of proteobacteria and deferribacterium funguses; in-vitro experiments show that the stropharia rugoso-annulata polysaccharide can increase the abundance of beneficial bacteria bacteroides, reduce the abundance of harmful bacteria Escherichia-Shigella and Enterococcus, and increase the content of short-chain fatty acids.

The invention discloses a raspberry homogeneous polysaccharide. The monosaccharide components of the raspberry homogeneous polysaccharide comprise fucose, rhamnose, arabinose, galactose, xylose, galacturonic acid, glucuronic acid and apiose. The main chain structure of the raspberry homogeneous polysaccharide is 1, 4-linked galacturonic acid pyranose, and the weight-average molecular weight of the raspberry homogeneous polysaccharide is 8.54 + / -5.0 kDa. The invention discloses a raspberry homogeneous polysaccharide component for inhibiting dietary oil absorption and preventing and improving obesity, which is prepared by the steps of water extraction and alcohol precipitation, ion exchange chromatographic column elution and permeation gel chromatographic column elution. The structure of the compound is analyzed by high performance gel permeation chromatography, infrared spectroscopy, ion chromatography, gas chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy. The homogeneous polysaccharide component can be used for improving obesity and fat tissue accumulation hypertrophy, and the efficacy of the homogeneous polysaccharide component is related to inhibition of absorption of dietary oil in the intestinal tract and promotion of discharge of the dietary oil into the body.

The present invention discloses roxburghii polysaccharide and its preparation method and application. Wherein roxburghii crude polysaccharide is purified to obtain two polysaccharides RP1 and RP3, RP1 monosaccharide types include galacturonic acid, galactose, rhamnose and arabinose, and its molar ratio is 1.00:3.45:1.88:1.82, RP3 monosaccharide types include galactose, rhamnose and arabinose, galacturonic acid, galactose, rhamnose and arabinose, and its molar ratio is 1.00:0.37:0.37:0.25. It has been confirmed by in vitro experiments that the above-mentioned roxburghii polysaccharide has the ability to significantly inhibit the proliferation of MCF-7 breast cancer cells, as well as the effect of inducing apoptosis of MCF-7 breast cancer cells, and can be developed to prepare breast cancer therapeutic drugs; At the same time, the above-mentioned roxburghii polysaccharide has no effect on normal L929 cells. Therefore, the above-mentioned roxburghii polysaccharide has broad application prospects and has good social and economic benefits.

The invention relates to the field of natural medicines, and particularly discloses Tibetan medicine scindapsus aureus flower polysaccharide A1 with a lipid-lowering function as well as a preparation method and application thereof. The Tibetan medicine scindapsus aureus flower polysaccharide A1 is prepared from the following components in mol percent: 55 to 60 percent of arabinose, 15 to 20 percent of galactose, 5 to 10 percent of galacturonic acid, 5 to 10 percent of rhamnose and 3 to 5 percent of glucose. The Tibetan medicine scindapsus aureus flower polysaccharide A1 is extracted and separated from Tibetan medicine scindapsus aureus flowers. The method comprises the following steps: S1, extracting and preparing Tibetan medicine scindapsus aureus flower total polysaccharide by adopting a water extraction and alcohol precipitation method; s2, separating and purifying the scindapsus aureus flower total polysaccharide by adopting an anion exchange chromatography technology to obtain EGP-A, and further separating and purifying the EGP-A by adopting a gel column chromatography technology to obtain EGP-A1. Through research and implementation of the invention, the EGP-A1 has good lipid-lowering activity, can play a role in protecting blood fat and cardiovascular health, and has a good medicinal prospect in the aspect of preparing lipid-lowering medicines.

The invention discloses purified barley seedling polysaccharide as well as a preparation method and application thereof. The polysaccharide is prepared from six monosaccharides, namely rhamnose, galacturonic acid, glucose, galactose, xylose and arabinose in a molar ratio of 2.88: 3.39: 1.51: 1: 0.76: 3.2. The relative molecular weight is 254.09 kDa. A fermentation method is combined with an innovative purification process, so that the barley seedling polysaccharide monomer with high purity and uniform structure is obtained for the first time. Through a multi-dimensional characterization technology, fine structure characteristics such as monosaccharide composition, glucosidic bond connection mode and branching degree are systematically analyzed, and a reliable material basis is provided for establishing structure-function accurate association. The purified barley seedling polysaccharide has a remarkable effect of promoting intestinal peristalsis, not only lays a scientific foundation for deep processing of barley seedlings and research and development of related functional products, but also provides a new theoretical support for relieving intestinal peristalsis disorder, and has a wide application prospect.

The invention discloses a method for purifying fructus mali pectin and application of the fructus mali pectin in ulcerative colitis, and belongs to the related technical field of separation and purification of natural product bioactive substances and the field of biological medicine. According to the purification method, impurities in the fructus mali pectin can be effectively removed, meanwhile, the structure of the fructus mali pectin cannot be remarkably changed, and the content of galacturonic acid and the esterification degree of the pectin obtained through purification are high. The fructus mali pure pectin can significantly reduce the serum proinflammatory factor level of DSS-induced ulcerative colitis mice, improve the expression of anti-inflammatory factors, and effectively improve the pathological injury of intestinal tissues. According to the invention, a high-efficiency pectin purification system based on macroporous adsorption resin is constructed, and an industrial solution is provided for separation of natural products; meanwhile, the anti-inflammatory mechanism of the fructus mali pure pectin disclosed by the invention lays a scientific foundation for developing medicines and functional foods for treating ulcerative colon.

Hippophae rhamnoides peel polysaccharides, and a preparation method therefor and a use thereof. The hippophae rhamnoides peel polysaccharides comprise the following monosaccharides: rhamnose, mannose, galactose, glucose, galacturonic acid, and arabinose. The preparation method comprises: degreasing, extracting, concentrating and performing alcohol precipitation to obtain water-soluble crude polysaccharides; and then using a non-polar macroporous adsorption resin to perform purification to obtain hippophae rhamnoides peel polysaccharides. The yield and content of the polysaccharides are high. By using the non-polar microporous adsorption resin to replace a relatively costly DEAE-cellulose and Sephadex gel, active polysaccharides in the Hippophae rhamnoides peel are enriched, the yield and purity of the polysaccharides are also greatly improved, and the polysaccharides have low production costs and are used for industrial batch production. The hippophae rhamnoides peel polysaccharides have significant effects of resisting ulcerative colitis, and alleviating constipation, indigestion, and intestinal flora disorder.

The invention discloses tartary buckwheat vinasse polysaccharide with antioxidant activity and a preparation method of the tartary buckwheat vinasse polysaccharide, and belongs to the technical field of polysaccharide. The molecular weight of the tartary buckwheat vinasse polysaccharide with the antioxidant activity is 3.84 * 10 < 5 >, and the monosaccharide is prepared from Man-mannose, Rib-ribose, Rham-rhamnose, GlcUA-glucuronic acid, GalUA-galacturonic acid, Glc-glucose, Gal-galactose, Xyl-xylose and Ara-arabinose according to the molar ratio of (41.60): (20.20): (1.70): (2.84): (4.45): (8.90): (14.39): (6.27): (5.82). The tartary buckwheat vinasse polysaccharide is subjected to crude extraction through an ultrasonic-assisted water extraction and alcohol precipitation method, the extracted crude polysaccharide is purified through ion exchange column and sephadex column chromatography, and the prepared tartary buckwheat vinasse polysaccharide has a good scavenging effect on ABTS < + > free radicals, DPPH free radicals and hydroxyl free radicals and has antioxidant activity.

The invention provides application of pitaya peel polysaccharide in preparation of a medicine for repairing skin wounds. The monosaccharide components of the pitaya peel polysaccharide comprise rhamnose, arabinose, galactose, glucose, xylose, mannose, galacturonic acid and glucuronic acid. Research finds that the dragon fruit peel polysaccharide remarkably accelerates the wound healing process and promotes granulation tissue formation and collagen deposition. Meanwhile, the pitaya peel polysaccharide can also promote cell proliferation and neovascularization at the skin wound part, exert an anti-inflammatory effect, remodel skin microbiota and provide a more suitable microenvironment for skin wound healing. The invention provides a new drug choice for clinically repairing skin wounds, and can be used for developing new skin wound dressings.

The invention provides a glycerophosphorylcholine-collagen peptide microcapsule and a preparation method and application thereof.The glycerophosphorylcholine-collagen peptide microcapsule takes glycerophosphorylcholine as a core material and takes a compound formed by polysaccharide containing galacturonic acid and hydrolyzed collagen peptide as a wall material, the preparation method comprises the following steps: preparing a glycerophosphorylcholine solution, activating polysaccharide containing galacturonic acid, reacting hydrolyzed collagen peptide with the polysaccharide containing galacturonic acid to prepare a wall material solution, homogenizing the glycerophosphorylcholine solution and the wall material solution, and performing spray drying to obtain the microcapsule. The microcapsule is applied to fruit juice beverages, oral liquid, solid beverages and tablets. By wrapping the glycerophosphorylcholine in the wall material, the problems that the glycerophosphorylcholine is easy to absorb moisture and poor in acid-base stability are solved.

The application discloses a kind of acanthopanax acid polysaccharides with intestinal protection function and its preparation method and application, belong to the field of functional food and biotechnology.The acanthopanax acid polysaccharide is by water extraction alcohol precipitation, after impurity removal, through DEAE-52 anion exchange column elution and collection 0.2 mol / L NaCl elution peak, and the uniform component obtained by Sephadex G-100 gel column chromatography purification.Its uronic acid content is 30%-40%, weight average relative molecular weight is 50-100kDa, mainly by glucose, galactose, galacturonic acid and arabinose, infrared spectrum has carboxyl characteristic absorption peak at 1736 cm-1 and 1615 cm-1.Experiments prove that the acanthopanax acid polysaccharide has antioxidant activity and hypoglycemic activity.The acid polysaccharide has protective effect on LPS-induced Caco-2 cell damage, can effectively reduce the secretion of pro-inflammatory factors TNF-α, IL-1β, IL-6, and improve the level of anti-inflammatory factor IL-10.The acanthopanax acid polysaccharide can be prepared into oral liquid, tablet candy, solid beverage and other functional food forms.

The invention discloses lotus leaf homogeneous polysaccharide LLP3-1 as well as a separation and purification method and application thereof, and belongs to the technical field of plant polysaccharide. The lotus leaf homogeneous polysaccharide LLP3-1 is composed of rhamnose, arabinose, galactose and galacturonic acid, the molar percentage of monosaccharide is 21.95: 25.33: 21.10: 31.62, the lotus leaf homogeneous polysaccharide LLP3-1 is acidic pectin polysaccharide with RG-I as a main structural domain and with part of side chains, the main chain is mainly composed of galacturonic acid and rhamnose, and the side chains are mainly composed of arabinose and galactose. The lotus leaf homogeneous polysaccharide LLP3-1 has the beneficial effects that the lotus leaf homogeneous polysaccharide LLP3-1 can obviously improve the symptoms of ulcerative colitis; the compound can be widely applied to preparation of medicines for treating ulcerative colitis, medicines for inhibiting proinflammatory factor secretion, antioxidation medicines, medicines for improving intestinal barrier integrity and functions, medicines for promoting short-chain fatty acid generation and medicines for improving intestinal flora disorder of ulcerative colitis.

The present invention provides a homogenized pumpkin polysaccharide and its preparation method and application, belonging to the technical field of polysaccharide extraction and purification. The homogenized pumpkin polysaccharide of the present invention contains mannose, glucosamine hydrochloride, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose, with the corresponding molar ratios being 0.005:0.004:0.041:0.013:0.545:0.004:0.241:0.147; the relative molecular weight of the homogenized pumpkin polysaccharide is 5.96×10 4 The homogenized pumpkin polysaccharide has significant lipid-lowering and blood sugar-lowering effects. The preparation method has mild process conditions and simple operation. The obtained polysaccharide has high purity and stable structure, and is suitable for industrial-scale production.

This invention provides a Shoumei polysaccharide, its preparation method, and its application, belonging to the field of biomedical technology. The Shoumei polysaccharide is a homogeneous polysaccharide with the repeating sequence →4)-α-D-Gal. p A‑(1→, →4)‑β‑D‑Gal p ‑(1→,→4,6)‑β‑D‑Gal p ‑(1→,→6)‑β‑D‑Gal p -(1→、α-L-Ara f ‑(1→,→5)‑α‑L‑Ara f ‑(1→,→4)‑β‑D‑Glc p -(1→; The molecular weight of the Shoumei polysaccharide is 1100 kDa; The monosaccharide composition of the Shoumei polysaccharide is arabinose, galactose, glucose and galacturonic acid; The molar ratio of arabinose, galactose, glucose and galacturonic acid is 10.9:12.1:4.8:72.2, and the degree of galacturonic acid esterification is 33%. The Shoumei polysaccharide of the present invention can treat and / or prevent depression.

This invention discloses the application of Uncaria rhynchophylla neutral polysaccharide URP-W in the preparation of anti-glioma drugs, belonging to the field of anti-tumor technology of medicinal plant polysaccharides. The invention obtains a crude polysaccharide extract from Uncaria rhynchophylla through hot water extraction and ethanol precipitation, followed by purification using a DEAE cellulose column and G200 dextran gel to obtain Uncaria rhynchophylla neutral polysaccharide URP-W. The monosaccharide composition of URP-W includes arabinose, rhamnose, galactose, glucose, xylose, mannose, galacturonic acid, and mannuronic acid in a molar ratio of 17.99:6.32:21.71:27.17:2.56:7.57:16.20:0.49. Experiments have shown that URP-W can inhibit the proliferation of gliomas and induce apoptosis, exhibiting significant anti-tumor activity against glioma cells, providing a new drug raw material and treatment method for the clinical treatment of gliomas.

The invention belongs to the technical field of biological medicine, and particularly relates to wheat bran araboxylan and application thereof. The invention provides wheat bran AX with specific molecular weight and monosaccharide composition. The wheat bran AX comprises the following monosaccharides: 0.20%-0.22% of glucuronic acid, 0.58%-0.62% of galacturonic acid, 0.21%-0.23% of rhamnose, 0.6%-0.7% of glucose, 1.4%-1.5% of galactose, 18%-19.2% of xylose and 21%-23% of arabinose. Compared with commercially available wheat bran AX, inulin, fructo-oligosaccharide and other common dietary fibers, the self-made wheat bran AX has higher diversity of microbial communities in the fermentation process, has a better intestinal flora regulating effect, further has a good relieving effect on the abnormal glucose and lipid metabolism of the body, and can be used for preventing and treating the abnormal glucose and lipid metabolism of the body. Therefore, the traditional Chinese medicine composition has a good regulation effect on various diseases such as non-alcoholic fatty liver and the like caused by abnormal glucose and lipid metabolism of the organism.

The present invention relates to a prebiotic composition for modulating the gut microbiota of a subject, said use comprising orally administering said prebiotic composition to said subject, wherein said composition comprises at least 0.1% by weight of dry matter of RG-I polysaccharide derived from fruit, carrot, pea, chicory or beet, said RG-I polysaccharide having a molecular weight of more than 15 kDa and having a backbone composed of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in α(1→4)-galacturonic acid-α(1→2)-rhamnose residues, wherein the molar ratio of galacturonic acid residues to rhamnose residues in said RG-I polysaccharide is in the range of 20:1 to 1:1.

The invention discloses preparation and application of a double-component dsRNA (double-stranded ribonucleic acid) medicament for enhancing resistance mutation risk capability of RNA (ribonucleic acid) pesticide to botrytis cinerea, and a key pathogenic gene of botrytis cinerea is any one or two of a botrytis cinerea global regulatory factor Vel1 gene or a galacturonic acid reductase Gar2 gene. The dsRNA is any one or two of dsRNAs targeting a Vel1 gene or a Gar2 gene, and efficient prevention and control of gray mold are achieved through key pathogenic links such as spore germination inhibition, hypha colonization and infection structure formation. In addition, the effectiveness of the RNA pesticide aiming at botrytis cinerea after single target gene mutation is evaluated through cooperative use of the combination of the double-component RNA, the ds-Gar2 and the ds-Vel1, the good effect of the double-target synergistic effect in the aspect of reducing the off-target risk is proved, and the practice and popularization of a green prevention and control technology in prevention and control of gray mold are promoted.